Jonathan S. Zager, MD, discussed the use of percutaneous hepatic perfusion vs best alternative care for patients with hepatic-dominant ocular melanoma analyzed in the phase 3 FOCUS trial.
2022
Novel Technique Reveals Surprising New Way to Suppress Tumor Cells
An enzyme (sAC) that produces cAMP moves in and out of the nucleus of melanoma cells and is missing from invasive cancer cells.
Using the power of proteomics to predict immunotherapy responses in melanoma and beyond
Next-generation proteomics has a vital role to play in the search for new biomarkers of immunotherapy response. Recent studies in melanoma presented at the European Society for Medical Oncology (ESMO) Congress highlight how these insights have the potential to transform cancer care.
Increased Melanoma Survival With Immunotherapy Followed by Targeted Therapy
A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received immunotherapy (72 percent survival rate) versus those who initially got targeted therapies (52 percent survival rate). Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on immunotherapy.